RBM39
RNA-binding protein 39
Also known as: CAPER, CAPERalpha, CC1.3, fSAP59, HCC1, RBM39_HUMAN, RNPC2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q14498
- Gene
- RBM39
- Ensembl
- ENSG00000131051
- Chromosome
- 20
- Canonical length
- 530 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nuclear speckles,Microtubules,Centriolar satellite
OverviewNCBI Gene
This gene encodes a member of the U2AF65 family of proteins. The encoded protein is found in the nucleus, where it co-localizes with core spliceosomal proteins. It has been shown to play a role in both steroid hormone receptor-mediated transcription and alternative splicing, and it is also a transcriptional coregulator of the viral oncoprotein v-Rel. Multiple transcript variants have been observed for this gene. A related pseudogene has been identified on chromosome X. [provided by RefSeq, Aug 2011]
Canonical amino-acid sequenceUniProt
530 residues, UniProt reviewed canonical sequence.
>Q14498|RBM39
1 MADDIDIEAM LEAPYKKDEN KLSSANGHEE RSKKRKKSKS RSRSHERKRS KSKERKRSRD
61 RERKKSKSRE RKRSRSKERR RSRSRSRDRR FRGRYRSPYS GPKFNSAIRG KIGLPHSIKL
121 SRRRSRSKSP FRKDKSPVRE PIDNLTPEER DARTVFCMQL AARIRPRDLE EFFSTVGKVR
181 DVRMISDRNS RRSKGIAYVE FVDVSSVPLA IGLTGQRVLG VPIIVQASQA EKNRAAAMAN
241 NLQKGSAGPM RLYVGSLHFN ITEDMLRGIF EPFGRIESIQ LMMDSETGRS KGYGFITFSD
301 SECAKKALEQ LNGFELAGRP MKVGHVTERT DASSASSFLD SDELERTGID LGTTGRLQLM
361 ARLAEGTGLQ IPPAAQQALQ MSGSLAFGAV AEFSFVIDLQ TRLSQQTEAS ALAAAASVQP
421 LATQCFQLSN MFNPQTEEEV GWDTEIKDDV IEECNKHGGV IHIYVDKNSA QGNVYVKCPS
481 IAAAIAAVNA LHGRWFAGKM ITAAYVPLPT YHNLFPDSMT ATQLLVPSRRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RBM39 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.48
- Highest tissue expression
- 162 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 162 nTPM
- thymus: 48 nTPM
- retina: 46 nTPM
- ovary: 45 nTPM
- urinary bladder: 43 nTPM
- skeletal muscle: 41 nTPM
Single-cell type
- neutrophils: 1,198 nCPM
- syncytiotrophoblasts: 803 nCPM
- megakaryocyte-erythroid progenitors: 729 nCPM
- nk-cells: 728 nCPM
- mast cells: 715 nCPM
- endometrial glandular cells: 697 nCPM
Immune cell
- neutrophil: 430 nTPM
- basophil: 252 nTPM
- eosinophil: 198 nTPM
- plasmacytoid DC: 161 nTPM
- naive B-cell: 141 nTPM
- memory B-cell: 132 nTPM
Brain region
- cerebellum: 93 nTPM
- cerebral cortex: 81 nTPM
- white matter: 78 nTPM
- hypothalamus: 75 nTPM
- medulla oblongata: 75 nTPM
- midbrain: 75 nTPM
ReferencesPubMed · IEDB
Publications for RBM39 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
2017 · Tumour Biol · RCR 1 · 29 citations - Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens.
2018 · Cancer Immunol Immunother · RCR 0.8 · 22 citations - Tumor-associated antigen CAPERα and microvessel density in hepatocellular carcinoma.
2016 · Oncotarget · RCR 0.4 · 11 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.21
- gnomAD pLI
- 1
- gnomAD missense Z
- 4.26
- DepMap mean gene effect
- -2.2
- DepMap dependency class
- pan
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 12% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RBM39 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RBM39 as an antibody target. Whether an autoantibody or antibody against RBM39 could matter depends on whether native RBM39 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RBM39 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RBM39 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...